Brill D M, Fozzard H A
Compr Ther. 1985 Oct;11(10):67-71.
CCB are a diverse group of drugs that bind to specific glycoprotein receptors associated with the cell membrane that are most likely identical to the voltage-sensitive calcium channel. By inhibiting the influx of calcium into myocardial, pacemaker, and conducting tissues and vascular smooth muscle, these agents modify excitation-contraction coupling in muscle and electrical impulse transmission in the heart. The vasodilating and electrophysiologic actions of these drugs have been harnessed for the treatment of coronary vasospasm, angina pectoris, and supraventricular arrhythmias. They also have great potential for the treatment of hypertension, cerebrovascular disorders, and Raynaud's phenomenon. Their utility in hypertrophic cardiomyopathy, congestive heart failure, myocardial preservation, and primary pulmonary hypertension has not been convincingly established. Future second-generation CCB may offer greater selectivity, improved side effect profiles, and an even wider range of actions.
钙通道阻滞剂是一类多样的药物，它们与细胞膜相关的特定糖蛋白受体结合，这些受体很可能与电压敏感性钙通道相同。通过抑制钙流入心肌、起搏组织、传导组织和血管平滑肌，这些药物改变肌肉中的兴奋 - 收缩偶联以及心脏中的电冲动传导。这些药物的血管舒张和电生理作用已被用于治疗冠状动脉痉挛、心绞痛和室上性心律失常。它们在治疗高血压、脑血管疾病和雷诺现象方面也有很大潜力。它们在肥厚型心肌病、充血性心力衰竭、心肌保护和原发性肺动脉高压中的效用尚未得到令人信服的确立。未来的第二代钙通道阻滞剂可能具有更高的选择性、更好的副作用谱和更广泛的作用范围。
